Chang Ken Cn, Marton Matthew J
Molecular Biomarkers & Diagnostics, Merck & Co, Inc., Rahway, NJ, USA.
Per Med. 2014 Nov;11(8):745-760. doi: 10.2217/pme.14.52.
MAPK pathway activation related to cancer development has drawn a great deal of attention in the field of personalized medicine in recent years. Many different approaches and assays have been developed to query the activation of this pathway and to develop life-saving treatments. The goal of this review article is threefold. First, to provide a brief overview of the many mutation assays that have been used to detect MAPK pathway activation, and to compare pros and cons of these assay platforms. Second, to focus on one custom-designed multiplexing mutation assay that is currently used to support an ongoing clinical trial and to show the novel features of this assay and its relevance in addressing unmet clinical needs. Third, to provide future perspectives of these MAPK pathway gene mutation detection efforts and to suggest how what we have learned from past and current approaches should guide future developments.
近年来,与癌症发展相关的丝裂原活化蛋白激酶(MAPK)信号通路激活在个性化医疗领域备受关注。人们开发了许多不同的方法和检测手段来探究该信号通路的激活情况,并研发挽救生命的治疗方法。这篇综述文章有三个目标。其一,简要概述用于检测MAPK信号通路激活的多种突变检测方法,并比较这些检测平台的优缺点。其二,重点介绍一种目前用于支持一项正在进行的临床试验的定制化多重突变检测方法,展示该检测方法的新颖特性及其在满足未被满足的临床需求方面的相关性。其三,提供这些MAPK信号通路基因突变检测工作的未来展望,并提出我们从过去和当前方法中学到的知识应如何指导未来的发展。